Gilead Sciences Inc (GILD)

[Tha Part Time Er]

In premarket trading on the stock market today, GILD stock popped 4% near 79.80. But AstraZeneca stock slipped 2.2% near 52.70.

The reports emerged over the weekend. Pharma giant AstraZeneca approached Gilead a month ago about a potential merger, according to Bloomberg, which cited people familiar with the matter. There have been no formal talks.


If successful, the tie-up would be the biggest health care deal on record since Bristol Myers Squibb (BMY) spent $74 billion last year to acquire biotech company Celgene.


Take the market with you
With our top-rated app >

Download Now

Shares of GILD stock have struggled for years amid a decline in its hepatitis C treatment franchise. Now, Gilead is making a big push into treating HIV and cancer. The biotech also makes a coronavirus treatment which has emergency authorization in the U.S.